Asset Management Company logo

Asset Management Company

North America, California, United States, Palo Alto

Description

Asset Management Company partner with visionary entrepreneurs and to help create valuable new companies and important new industries.

Investor Profile

Asset Management Company has made 33 investments, with 0 in the past 12 months and 15% as lead.

Stage Focus

  • Series B (24%)
  • Series C (18%)
  • Series A (18%)
  • Series Unknown (12%)
  • Debt Financing (12%)
  • Series D (12%)
  • Series E (3%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Neuroscience
  • Medical
  • Therapeutics
  • Mobile
  • Software
  • Medical Device
  • Enterprise Software
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Asset Management Company frequently co-invest with?

Vulcan Capital
North America, Washington, United States, Seattle
Co-Investments: 3
Canaan Partners
North America, California, United States, Menlo Park
Co-Investments: 5
Domain Associates
North America, California, United States, San Diego
Co-Investments: 2
Sanderling Ventures
North America, California, United States, San Mateo
Co-Investments: 3
PolyTechnos Venture Partners
Europe, Bayern, Germany, Munich
Co-Investments: 3
EDF Ventures
North America, Michigan, United States, Ann Arbor
Co-Investments: 2
The Angels' Forum
North America, California, United States, Mountain View
Co-Investments: 2
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 2
Asset Management Ventures (AMV)
North America, California, United States, Palo Alto
Co-Investments: 12
Quantum Technology Partners
North America, California, United States, San Jose
Co-Investments: 3

What are some of recent deals done by Asset Management Company?

InteKrin

Los Altos, California, United States

InteKrin Therapeutics is focused on developing and commercializing therapeutics for neuroendocrine, metabolic and immune disorders.

BiotechnologyNeuroscienceTherapeutics
Series UnknownJun 14, 2010
Amount Raised: $2,292,809
Biomimedica

South San Francisco, California, United States

Biomimedica is a medical device company that is pioneering new approaches to repair joints through synthetic cartilage technology.

Health CareMedicalMedical Device
Debt FinancingApr 12, 2010
Amount Raised: $250,000
Chimerix

Durham, North Carolina, United States

Chimerix is a biotechnology company developing therapeutics for antiviral diseases.

BiotechnologyHealth CarePharmaceutical
Series EAug 10, 2009
Amount Raised: $16,100,000
Sonoma Orthopedics

Santa Rosa, California, United States

Sonoma Orthopedic Products designs, develops and delivers proprietary orthopedic implants for physicians to treat problematic fractures.

BiotechnologyHealth CareHospitalMedical Device
Series CApr 6, 2009
Amount Raised: $12,000,000
InteKrin

Los Altos, California, United States

InteKrin Therapeutics is focused on developing and commercializing therapeutics for neuroendocrine, metabolic and immune disorders.

BiotechnologyNeuroscienceTherapeutics
Series UnknownApr 2, 2009
Amount Raised: $21,391,923
BiPar Sciences

Brisbane, California, United States

BiPar Sciences is a pharmacological company developing PARP inhibitors as cancer therapies.

BiotechnologyHealth CarePharmaceutical
Series CJan 12, 2009
Amount Raised: $20,000,000
InteKrin

Los Altos, California, United States

InteKrin Therapeutics is focused on developing and commercializing therapeutics for neuroendocrine, metabolic and immune disorders.

BiotechnologyNeuroscienceTherapeutics
Series CAug 4, 2008
Amount Raised: $18,500,000
Proteus Digital Health

Redwood City, California, United States

Proteus Digital Health develops digital medicines that collect and aggregate various behavioral, physiological and therapeutic metrics.

Health CareMedicalMobilePharmaceutical
Series DAug 2, 2008
Amount Raised: $28,626,000
BiPar Sciences

Brisbane, California, United States

BiPar Sciences is a pharmacological company developing PARP inhibitors as cancer therapies.

BiotechnologyHealth CarePharmaceutical
Series BApr 16, 2008
Amount Raised: $625,000
InteKrin

Los Altos, California, United States

InteKrin Therapeutics is focused on developing and commercializing therapeutics for neuroendocrine, metabolic and immune disorders.

BiotechnologyNeuroscienceTherapeutics
Debt FinancingFeb 15, 2008
Amount Raised: $533,361